ArticleFrontiers in pharmacology2026
Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Montmorillonite powder (MP) can adsorb pyrotinib and reduce its bioavailability. This study investigated the effects of different dosing intervals on the pharmacokinetic interaction between MP and pyrotinib in rats. Methods: Eighteen male Sprague-Dawley rats were randomly assigned to three groups (n = 6/group): Control (pyrotinib alone), 0.5-h interval (MP given 0.5 h after pyrotinib), and 2.0-h interval (MP given 2.0 h after pyrotinib). Pyrotinib (10 mg/kg) was orally administered to all rats, followed by MP (240 mg/kg) or water (control) at designated time points. Blood samples were collected up to 24 h post-dose. Plasma pyrotinib concentrations were determined by a validated liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated using WinNonlin. Results: The 0.5-h interval group showed substantially reduced pyrotinib exposure, with area under the curve (AUC) from time zero to last time point (AUC Conclusion: In rats, MP administration at an insufficient dosing interval markedly compromises pyrotinib systemic exposure, whereas adequate temporal separation largely mitigates this interaction. These findings underscore the urgent need for dedicated clinical pharmacokinetic studies to define the optimal dosing interval in humans and to minimize the risk of subtherapeutic pyrotinib exposure in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.